Wellcome’s new head on the future of clinical research funding
BMJ 2024; 386 doi: https://doi.org/10.1136/bmj.q1257 (Published 16 September 2024) Cite this as: BMJ 2024;386:q1257- Mun-Keat Looi
- The BMJ
- mlooi{at}bmj.com
John-Arne Røttingen, like his predecessor, the infectious disease specialist Jeremy Farrar,1 is a doctor. He’s also a former global health ambassador for his home country of Norway and led its state funding body, the Research Council of Norway.
“I’m a physician scientist. I’ve been really motivated by this sort of science—that’s why I started studying medicine,” he tells The BMJ. He studied medicine at the University of Oslo and, among other qualifications, holds an MSc from the University of Oxford.
His research has covered basic science, epidemiology, clinical trials, health services research, and global health policy. Notably, he led the steering groups for the Ebola vaccine trial in Guinea and the Covid-19 WHO Solidarity trial. “Through the Ebola outbreak of West Africa [in 2014-16], I became really engaged with the need for a long term commitment on the issue of innovation and access to medicines—and how we find models for innovating where there are no commercial …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.